Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. A number ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in t ...

Research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Dynavax Technologies in a report ...

Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...

The Emeryville, California-based company said it had net income of 5 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...